Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

A new study provides detailed information about the molecular level binding interaction pattern of the SARS-CoV-2 Omicron and wt variant with the hACE2 receptor

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

An integrated computational methodology for COVID drug prioritization

Researchers recently published a study in the journal Briefings in Bioinformatics wherein they integrated multiple bioinformatics and cheminformatics-based methods to prioritize drugs for the treatment of COVID-19.

29 Dec 2021

Omicron analysis shows no clear evidence for increased virulence or lethality

Researchers conducted a genomic sequencing and epidemiological correlation analysis of the SARS-CoV-2 Omicron variant.

29 Dec 2021

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

A new study found that the presence of a subset of antibodies with broad neutralizing activities against all circulating variants of concern in the three-dose vaccines' memory B-derived antibody repertoire suggests that the Omicron/future variants infection may elicit selective and rapid recall of humoral responses, conferring secondary protection directed by memory etched in the immune system.

29 Dec 2021

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Now in new research, scientists from the University of Leicester have been investigating how these mutations alter the affinities of RBDs to ACE2.

28 Dec 2021

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Researchers from the University of Colorado Anschutz Medical Campus have been investigating the changes imparted on the Gamma variant by three RBD mutations.

28 Dec 2021

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

28 Dec 2021

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

The Omicron spike is relatively poorly cleaved and impaired in mediating cell-cell fusion and syncytia formation, contrary to predictions.

28 Dec 2021

Researchers discover antibodies that neutralize omicron and other SARS-CoV-2 variants

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate.

28 Dec 2021

Cryo-EM of Omicron variant reveals antibody evasion by spike-ACE2 complex

Researchers compare the obtained binding affinities to wild-type and Delta spike proteins to determine the impact of Omicron mutations.

23 Dec 2021

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

Scientists used virus-like particles and found that Omicron showed increased infectivity, relative to the B.1 and B.1.1 strains, which was similar to the Delta variant.

23 Dec 2021

Exploring why children have milder COVID-19 infections compared to adults

A new study has revealed that an activated pre-exposure innate interferon response in airways together with significantly reduced systemic interferon-stimulated populations are associated with relatively milder severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children.

23 Dec 2021

Angiotensin News and Research

Further Reading

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

How much do mutations reduce vaccine effectiveness in the Omicron variant?

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

An integrated computational methodology for COVID drug prioritization

Omicron analysis shows no clear evidence for increased virulence or lethality

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

Researchers discover antibodies that neutralize omicron and other SARS-CoV-2 variants

Cryo-EM of Omicron variant reveals antibody evasion by spike-ACE2 complex

Omicron has enhanced infectivity that is only weakly neutralized by vaccination or prior infection

Exploring why children have milder COVID-19 infections compared to adults

Protein-based nanoparticle vaccines for protection against SARS-CoV-2

COVID can affect sperm quality for three months

Role of novel SARS-CoV-2-derived svRNAs and the involvement of tRF in COVID-19

Omicron evades roughly twice the number of SARS-CoV-2 neutralizing antibodies than Delta

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News